Kenvue Inc. (KVUE)
Kenvue News: Why Investors Are Loving KVUE Stock This Week
Among the key stocks in focus in today's session is Kenvue (NYSE: KVUE ). The company, which was spun off from parent Johnson & Johnson (NYSE: JNJ ) almost exactly one year ago, is seeing strong traction in the market today.
Kenvue Is the S&P 500 Stock After Earnings. Here's Why.
Shares of the Band-Aid parent are on track for their largest daily percent increase on record.
Compared to Estimates, Kenvue (KVUE) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Kenvue (KVUE) Q2 Earnings and Revenues Beat Estimates
Kenvue (KVUE) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.32 per share a year ago.
Kenvue stock up 9% after earnings beat; consumer health stars
Shares in Kenvue Inc (NYSE:KVUE) were up 9% in pre-market trading after the company exceeded Wall Street's expectations for second-quarter profit and revenue. The consumer health company, spun off from Johnson & Johnson (NYSE:JNJ) last year, reported strong sales in its essential health products unit, which includes Tylenol, Listerine, and Neutrogena.
Kenvue's stock jumps as Band-Aid, Tylenol parent beat profit and sales expectations
Shares of Kenvue Inc. KVUE, -3.35% jumped 3.4% in premarket trading Tuesday, after the parent of consumer health brands including Band-Aid, Tylenol and Listerine reported second-quarter earnings that beat expectations, boosted by productivity gains and higher pricing. Net income fell to $58 million, or 3 cents a share, from $430 million, or 23 cents a share, in the year-ago period.
Listerine maker Kenvue beats estimates on strong essential health product sales
Kenvue beat Wall Street estimates for second-quarter profit and revenue on Tuesday, helped primarily by better-than-expected sales in its essential health products unit that sells brands including Band-Aid, Listerine and Carefree.
Is Kenvue The Next Big Dividend (Growth) Stock?
Kenvue stock has not participated in the recent rotation into value stocks. It trades at a forward P/E of 16 and a free cash flow yield of 6%. Such a valuation is indeed rare to find in the - typically overvalued - consumer staples sector, as is a starting dividend yield of 4.4%. In this article, I explain the main reasons for my growing enthusiasm and why I expect to initiate a long position in KVUE stock shortly.
Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
53 July Dividend Kings: Buy 8, Watch 8 More
"What is a Dividend King? A stock with 50 or more consecutive years of dividend increases."—suredividend.com. The 53 Dividend Kings, screened as of July 8, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 18.24%-30.31% topped-by Kenvue, and Genuine Parts. By yield, Altria tops-all. Top-ten July listings: SWK, FRT, KVUE, FTS, UBSI, BKH, NWN, CDUAF, UVV, MMM, & MO averaged 5.37% in yield.
Kenvue: Portfolio Of Products Can Be Replaced With Generic Brands
Kenvue (KVUE) was created as the result of a spinoff from Johnson & Johnson and encompasses the consumer side of the business. KVUE manages a wide array of products within each segment, but sales volume remains vulnerable to consumer spending. Data shows us that consumers are willing to go with store-branded generics as an alternative to name brands under KVUE's umbrella to save money.
3 Healthcare Stocks to Buy Now: May 2024
It's a great time to be looking at healthcare stocks to buy now. According to research from BlackRock, U.S. healthcare stocks have outperformed the overall stock market by an average of 10% over the past seven recessions.
